Introduction
Twist-1 is a highly conserved member of a family of regulatory basic helix-loop-helix (bHLH) transcription factors (Thisse et al., 1987) . bHLH proteins form active dimers with E-box proteins and bind to a core sequence (CANNTG, referred to as E-box) in the regulatory elements of many lineage-specific genes in muscle, cartilage and osteogenic cells. Germ-line mutations of the Twist-1 gene that result in haploinsufficiency lead to the development of one of the most commonly inherited craniosynostosis conditions, the Saethre-Chotzen syndrome, which is characterized by premature fusion of cranial sutures and limb abnormalities (Gripp et al., 2000; Ghouzzi et al., 2001; Yang et al., 2004; Cai and Jabs, 2005) . Expression of Twist-1 has also been implicated in the inhibition of differentiation of various cell lineages including osteoblasts and myoblasts (Spicer et al., 1996; Bialek et al., 2004; Hayashi et al., 2007) .
There are many reports that Twist-1 is involved in oncogenesis in a wide variety of human cancers by inhibiting apoptosis and promoting cell survival after DNA damage or oncogene activation. For example, Twist-1 participates in malignant transformation in neuroblastoma, where it cooperates with the amplified N-Myc oncogene to inhibit p53-mediated apoptosis (Valsesia-Wittmann et al., 2004) ; reviewed by Puisieux et al. (2006) . Twist-1 can induce an epithelial mesenchymal-like transition, proposed to be an important step in tumorigenesis and metastasis (Yang et al., , 2006 Smit et al., 2009) . A recent study also suggests Twist-1 involvement in tumor progression through direct activation of its transcriptional target YB-1 (Shiota et al., 2008) . Twist-1 expression can be regulated by hypoxia-induced HIF-1 through direct binding to the hypoxia-response element in the TWIST proximal promoter. This signaling pathway is thought to promote metastasis in response to intratumoral hypoxia (Yang et al., 2008) .
Elevated Twist-1 expression is correlated with a poor prognosis and high risk of metastasis in breast, prostate, ovarian, cervical and many others human cancers (Elias et al., 2005; Kwok et al., 2005; Mironchik et al., 2005; Kyo et al., 2006; Puisieux et al., 2006; Hosono et al., 2007; Shibata et al., 2008) . Recent reports suggest that high levels of Twist-1 confer cancer cells resistance to various chemotherapeutic drugs (Pham et al., 2007; Zhang et al., 2007; Shiota et al., 2008) .
PKB/Akt protein kinase has a pivotal role in cell signaling in response to a variety of extracellular stimuli, such as growth factors and cytokines, as well as g-irradiation (Bozulic et al., 2008 ). An intact protein kinase B (PKB) signaling is essential for cell growth and proliferation, whereas loss or gain of the function of this kinase is associated with complex diseases such as type II diabetes and cancer (for review see Fayard et al. (2005) and Yoeli- Lerner and Toker (2006) ). A somatic mutation (E17K) in the lipid-binding pocket of PKBa was identified recently in human breast, colorectal and ovarian cancers. This mutation resulted in pathological localization of the kinase to the plasma membrane, increasing activation and downstream signaling, that can induce oncogenic transformation of mouse lymphocytes (Carpten et al., 2007; Restuccia and Hemmings, 2009 ). Many PKB substrates have been identified in the nucleus. PKB phosphorylation of forkhead transcription factors inhibits their transcriptional activity by promoting their association with 14-3-3 regulatory proteins, retention in the cytoplasm and subsequent ubiquitination (Biggs et al., 1999; Kops et al., 1999) . Phosphorylation of the CDK inhibitor p27 impairs its nuclear import and opposes cell-cycle arrest (Liang et al., 2002) , whereas phosphorylation of p21 prevents its nuclear localization and interaction with CDK2 (Zhou et al., 2001) . So far, PKB and Twist-1 have not been identified as members of the same signaling cascade, but several reports have suggested their mutual regulation. Twist-1 transactivates the PKBb promoter and a positive association between elevated levels of Twist-1 and PKBb has been found in late-stage breast cancer samples (Cheng et al., 2007) . PKB in turn might behave as a functional mediator of Twist-1 and is involved in Twist-mediated chemotherapeutic drug resistance (Cheng et al., 2007; Zhang et al., 2007) . Interestingly, Saethre-Chotzen syndrome resulting from Twist-1 haploinsufficiency displays decreased expression of Cbl ubiquitin ligase, resulting in the accumulation of phosphatidylinositol-3-kinase (PI3K) and increased PI3K/PKB signaling (Guenou et al., 2006) .
Here we show that PKB kinase becomes activated and phosphorylates transcription factor Twist-1 at Ser42 in MCF-7 cells after g-irradiation and DNA damage induced by adriamycin. This post-translational modification of Twist-1 is necessary for the subsequent decrease in total p53 level and the inhibition of cellcycle arrest and apoptosis by impaired activation of p53 target genes. Moreover, Twist-1 Ser42 phosphorylation occurs in particular human cancers, especially colorectal and breast, and to a lesser extent lung and prostate. The results presented provide evidence that Twist-1 is a novel PKB nuclear substrate and establish a link between PKB activation and the downregulation of the p53 tumor suppressor.
Results
PKB phosphorylates Twist-1 in vitro at Ser42 and Ser123 PKB signaling pathway is one of the most frequently altered in human cancer (Yoeli-Lerner and Toker, 2006; Franke, 2008) , and yet there are few data directly implicating downstream targets of PKB in an oncogenic switch and cancer progression. As transcription factor Twist-1 was proposed recently to be a potent inducer of malignant transformation, we examined whether this protein is a PKB substrate. Four sites in human Twist-1 (Ser42, Ser45, Thr121 and Ser123) are predicted to be phosphorylated by PKB (Figure 1a) . Three of them (S42, T121 and S123) display the canonical PKB substrate consensus motive: K/RXK/RXXS/T (Supplementary Figure S1A ). Two N-terminal sites are situated in the low-complexity region of the molecule, whereas Thr121 and Ser123 lie within the bHLH domain, responsible for dimerization and DNA binding activity of Twist-1. We tested the ability of recombinant PKBb to induce phosphorylation of synthetic peptides comprising PKB recognition motifs and corresponding phosphosites, as well as their mutated analogs Ser42A, Ser45A, Thr121A and Ser125A. Only substitution of serine to alanine at positions 42 and 123 resulted in almost complete loss of phosphorylation of the corresponding peptide by PKB (Figure 1b ). Next, we tested the ability of PKB to phosphorylate the full-length Twist-1 protein. To control the specificity of the in vitro kinase reaction, we used an inactive PKBb (Figure 1c) . To further investigate which of the potential sites are preferentially phosphorylated in the full-length Twist-1, we performed a series of in vitro kinase assays followed by mass spectrometry (MS) analysis. Protein identification was done with MASCOT (Perkins et al., 1999) and relative quantification by multiple reaction monitoring (MRM) was performed as described by Hess et al. (2008) . This identified two phosphopeptides corresponding to Twist-1 amino-acid sequences containing S42 (Figure 1d ) and S123 (Figure 1e ) phosphosites. A more detailed MS analysis using inactive PKBb and recombinant Twist-1 mutants (summarized in Figure 1f ) confirmed that PKB phosphorylates Twist-1 in vitro on two residues S42 and S123. An example of a liquid chromatography (LC)-MS comparison of the LysC digests of GST-Twist-1 WT and GST-Twist-1 S42A mutants phosphorylated in vitro by recombinant PKBb is presented in Supplementary Figure S1 .
PKB phosphorylates Twist-1 at Ser42 in vivo As our results indicated that PKB phosphorylates Twist-1 in vitro, we examined whether this is also the case in cell culture. Immunoprecipitated Twist-1 was detected with the pan-PKB phosphosubstrate antibody in serum-stimulated cells but not in starved HEK293 cells (Supplementary Figure S2A) . Moreover, pretreatment of the cells with an inhibitor of the PI3K/PKB pathway (LY 294002) resulted in a strong reduction in the phospho-signal, suggesting a specific phosphorylation by PKB (Figure 2a and Supplementary Figure  S2B) . Treatment of cells with l-phosphatase almost completely abolished Twist-1 phosphorylation, confirming that Twist-1 exists as a phosphoprotein in cells. Importantly, because phosphorylation of the Twist-1 S42A mutant was not detected but the S123A mutant was phosphorylated as efficiently as the wild-type Twist-1, the results suggested preferential phosphorylation of S42 in vivo (Figure 2a and Supplementary Figure S2A) . Nevertheless, the pan-PKB phosphosubstrate antibody recognized Twist-1 phosphorylated on S42 or Ser123 in vitro equally well (Supplementary Figure S2C) , indicating that the antibody is capable of detecting both phosphosites.
To study the function of PKB-mediated Twist-1 phosphorylation in cells, we generated antibodies against the two phosphosites S42 and S123. Thorough characterization (Supplementary Figure S3A) confirmed the phosphospecificity of the antibodies in the in vitro kinase assay using wild-type or mutant Twist-1 proteins as substrates (Figure 2b ). To verify that Twist-1 can be phosphorylated under physiological conditions, we stimulated starved HEK293 cells with serum to induce PKB activity. Importantly, in these conditions phosphospecific antibodies detected Twist-1 only when phosphorylated at S42 but not at S123 (Figure 2c ). Previously, it was shown that S123 can be phosphorylated by protein kinase A (Firulli and Conway, 2008) . Indeed, stimulation of cells with forskolin resulted in phosphorylation of Twist-1 at S123, which was also detected by our aTwist-P-Ser123 antibody, thus confirming its specificity (Supplementary Figure S2D) . Altogether, these data indicate that PKB preferentially phosphorylates Twist-1 at S42 in cells. To further show specific role for PKB in the regulation of Twist-1 phosphorylation, we decreased the level of endogenous PKB kinase using shRNA. Twist-1 S42 phosphorylation was not induced after serum stimulation of cells with a low PKB content (Figure 2d ). (Blom et al., 2004) . (b) Twist-1 wild-type and mutant peptides were synthesized and named as follows: RKRRSSRRSAGG, S42/S45; RKRRSARRSAGG, S42A; RKRRSSRRAAGG, S45A; RERQRTQSLNEA, T121/S123; RERQRAQSLNEA, T121A; RERQRTQALNEA, S123A. The peptides were used in in vitro kinase assays with recombinant PKBb. The results shown come from duplicate assays in three independent experiments. The data are mean±standard deviation. The P-values were as follows: S42A, 0.0083 **; T121A, 0.093 (not significant); T123A, 0.0059 **. (c) GSTTwist-1 was in vitro phosphorylated in the presence of g- PKB phosphorylation of Twist-1 at Ser42 regulates Twist-1-mediated inhibition of the p53 response on DNA damage Taking into account the role of PKB as a pro-survival factor and our recent finding that PKB can be activated in the nucleus in response to DNA double-strand breaks (Bozulic et al., 2008) , we hypothesized that phosphorylation of Twist-1 at S42 has a role in promoting cell survival after DNA damage-induced stress. To test this hypothesis, we knocked down endogenous PKB in MCF-7 cells (human breast cancer cell line, with a functional p53) expressing Twist-1 and then treated them with g-irradiation. This resulted in PKB-dependent phosphorylation of Twist-1 at S42 (Figure 3a) . 
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Figure 2 Human Twist-1 is phosphorylated in vivo by PKB at Ser42 but not at Ser123. (a) Flag-tagged Twist-1 WT, Ser42A and Ser123A expressed in serum-stimulated HEK293 cells were immunoprecipitated with aFlag antibody and phosphorylated proteins detected with the aPKB phosphosubstrate antibody. Two of the precipitates were treated with l-phosphatase (100 U) and LY294002 (50 mM) added before stimulation, as indicated. (b) GST-Twist-1 WT and corresponding mutant proteins were phosphorylated in vitro by recombinant PKBb followed by SDS-PAGE and analysis by western blotting with the specific a-Twist-P-Ser42 and aTwist-PSer123 antibodies. (c) HEK293 cells expressing Flag-tagged Twist-1 WT, Ser42A, Ser123A or the Ser42,123/AA (SS/AA) double mutant were stimulated with serum for the times indicated and analyzed by western blotting with the aTwist-P-Ser42 and aTwist-PSer123 antibodies. (d) HEK293 cells expressing shRNA against PKB were stimulated with serum; Twist-1 phosphorylation was detected by western blotting with the aTwist-P-Ser42 antibody.
PKB-mediated Twist-1 phosphorylation Phosphorylation of Twist-1 at Ser42 by PKB regulates Twist-1-mediated inhibition of p53 on DNA damage. (a) MCF-7 cells expressing either control shRNA or shRNA against PKB were g-irradiated (10 Gy). Cells 2 h after irradiation were harvested and analyzed by western blotting. (b) MCF-7 cells transfected with empty vector (pB) as a control or stably expressing WT or mutant Twist-1 proteins Ser42Ala (S42A) and Ser42Glu (S42E) were g-irradiated (10 Gy) and then harvested after the times indicated. The induction of p53, p21
Waf1 and Mdm2 as well as the phosphorylation of Ser42 of Twist-1 and Ser473 of PKB were analyzed by western blotting. (c) H1299 cells were transfected with a combination of different plasmids as indicated below. At 24 h after transfection, cells were processed and luciferase activity measured. The results are from duplicate assays from three independent experiments showing mean ± standard deviation; asterisk Po0.005. (d) MCF-7 cells stably expressing Twist-1 or its mutants were g-irradiated (10 Gy). Cells 24 h after irradiation were fixed and the cell-cycle distribution analyzed by flow cytometry (top). The diagram displays the quantitative differences between the numbers of irradiated and control (non-irradiated) cells in G0/G1 and in G2 (bottom). The results are from three independent experiments expressed as mean±standard deviation.
PKB-mediated
Stable MCF-7-Twist-1 cell lines were then generated expressing Twist-1 and its variants at protein levels similar to endogenous (set1 in Supplementary Figure  S5A) . Notably, the expression of wild-type Twist-1 but not the S42A mutant led to a considerable decline in p53 induction on DNA damage (Figure 3b ). The effect of the expression of the S42E mutant did not differ from the wild type. Transient expression of Twist-1 and its mutants in MCF-7 cells had a similar effect (data not shown). After the suppressed p53 response, p21
Waf1 induction at both transcriptional ( Figure 3c ) and protein levels ( Figure 3b ) was decreased in the presence of wildtype Twist-1 but not of S42A Twist-1 mutant, suggesting a potential role of S42 phosphorylation in cell-cycle regulation. Indeed, both wild-type and S42E Twist-1-expressing cells escaped G1 cell-cycle arrest, whereas control cells and cells expressing phospho-deficient S42A Twist-1 accumulated in G1 in response to DNA damage (Figure 3d , top). Quantitative cell-cycle analysis showed a significant rescue effect of Twist-1 S42 phosphorylation on G1 phase arrest after g-irradiation, indicating that S42 phosphorylation confers the ability to progress through the cell cycle even under genotoxic stress (Figure 3d , bottom).
PKB-dependent phosphorylation of Twist-1 at Ser42 is essential for Twist-1-mediated survival after DNA damage-induced stress Given that activation of PKB and Twist-1 phosphorylation occurred in response to DNA damage and led to impaired induction of p53, we were prompted to investigate the functional relevance of this phosphorylation in the apoptotic process. For this, we used adriamycin to induce DNA double-strand breaks in MCF-7 cells. Cells expressing wild-type or S42E Twist-1 were less prone to develop morphological signs of apoptosis such as membrane blebbing and cellular shrinkage than control cells or cells expressing the S42A Twist-1 mutant (Figure 4a ). Similarly, in the same experimental conditions, wild-type or S42E Twist-1 expression significantly reduced cleavage of PARP (Figure 4b , bottom) and protection of cells from apoptosis was further confirmed by assessing the mitochondrial membrane potential (DCm) (Figure 4b ). This protection from apoptosis was not observed in the S42A mutant expressing cells. Conversely, shRNAmediated reduction of the wild-type Twist but not S42A mutant in MCF-7-Twist-1 cell lines resulted in increased sensitivity toward DNA damage ( Figure 4c ). As expected, S42A Twist-1 was also less potent in downregulating the pro-apoptotic p53 transcriptional target Bax (Figure 4d ). Taken together, these data confirm that phosphorylation of S42 is an important part of Twist-1-mediated anti-apoptotic effects.
Cancer in various organs is associated with Twist-1 Ser42 phosphorylation Previous results showed that Twist-1 phosphorylation at Ser42 has a significant role in the overall pro-survival effect of Twist-1. It is also well established that an abnormal cell cycle and resistance to apoptosis are typical hallmarks of cancer. This, together with our finding that S42 phosphorylation of Twist-1 promoted cell survival on genotoxic stress, prompted us to examine S42 phosphorylation in various tumors.
As it has been shown that Twist-1 is transcriptionally active in developing mouse embryos, we tested our aTwist-P-Ser42 antibody on paraffin-embedded sections of mouse embryos (Supplementary Figure S3B) . Strong expression was observed in areas known to have active Twist-1 (Gitelman, 1997) . We then applied the aTwist-P-Ser42 antibody to stain for phosphorylated Twist-1 on an array of paraffin-embedded primary cancer specimens. Remarkably, prominent S42 phosphorylation of Twist-1 was detected in 50% of 30 colon and 71% of 20 rectal cancers, but not in normal human colorectal tissue. Furthermore, 70% of 39 human breast cancer samples tested positive (Figure 5a ), whereas a smaller but still significant number of samples were positive in prostate (24%) and lung (35%) cancers (Figure 5a , bottom). In contrast, Ser42 phosphorylation was not detected in either normal or malignant tissues of human esophagus, stomach, liver or kidney (data not shown). However, it would be of interest to test a larger sample size of this group of negatively stained tumors to determine if Twist-1 S42 phosphorylation is indeed found only in select tissues. The same human tumors were then stained with phospho-PKB (Ser473) antibody to show the status of PKB activation. The analysis of staining for activated PKB displayed a high correlation with phosphorylated Twist-1. Particularly, cancers from rectum (78%) and breast (73%) stained positive for both phosphorylated Ser42 of Twist-1 and Ser473 of PKB. Consistent with this, we observed a strong phospho-Twist signal associated with elevated active PKB levels in neoplastic breast lesions of PTEN þ /À mice (Figure 5b) . Collectively, our data identify Twist-1 as a novel PKB substrate that becomes phosphorylated by PKB on Ser42 in the N-terminal part of the protein on serum stimulation and genotoxic stress. This phosphorylation appears to have a significant role in the ability of Twist-1 to downregulate the DNA damage-induced p53 response, thus promoting cell survival, which in turn may result in uncontrolled cell overgrowth and cancer (summarized schematically in Figure 5c ).
Discussion
The PKB substrate consensus sequence surrounding Ser42 in Twist-1 is evolutionary conserved in vertebrate genomes. In contrast, the Ser42 residue is not conserved in Hand proteins, the closest relatives of Twist-1 in the HLH family, suggesting that this site is phosphorylated in various species exclusively in Twist-1 and not other HLH transcription factors (Supplementary Figure S1A) . Moreover, this phosphorylation may have a function distinct from those of other known Twist-1 phosphosites. Protein kinase A phosphorylates two conserved PKB-mediated Twist-1 phosphorylation A Vichalkovski et al residues within the HLH domain of both Twist-1 and Hand2 (T125/S127 and T112/S114, respectively, in mice and T121/S123 and T112/S114 in human) bringing about their dimerization, which is necessary for the regulation of target genes during limb development. A group of Twist-1 mutations identified in patients with Saethre-Chotzen syndrome was reported to disrupt protein kinase A-mediated phosphorylation, emphasizing the importance of Twist-1 in development (Firulli et al., 2005) . In contrast to the S42A mutation, most mutations within the bHLH domain of Twist-1 negatively affect its transcriptional repressor function (Sosic et al., 2003) . Despite Ser42 being located adjacent to a putative NLS of Twist-1 (mutation of Arg39 to Gly present in a patient with mild Saethre-Chotzen syndrome, results in nuclear exclusion of Twist-1 (Funato et al., 2005; Singh and Gramolini, 2009 ), phosphorylation of Twist-1 by PKB did not influence protein localization (Supplementary Figure S4) . Even though the relevance of Twist-1 in cancer development has been studied intensively, there are few reports describing its molecular regulation. We report here that Twist-1 is phosphorylated at Ser42 by PKB (1) in response to serum stimulation of HEK293 cells, (2) in MCF-7 breast cancer cells after g-irradiation and adriamycin treatment and (3) in human cancer tissues of different origins thereby suggesting that Ser42 phosphorylation is involved in the regulation of cell growth and cell survival on DNA damage.
Focusing on the molecular events triggered by phosphorylation of Twist-1 by PKB in response to DNA damage, one of our key observations is that Ser42 phosphorylation is involved in the downregulation of the p53 tumor suppressor. p53 has a pivotal role in directing cell responses to various stress stimuli, and p53-controlled transactivation of target genes is an essential feature of each stress-response pathway, although some effects of p53 may be independent of transcription (Kruse and Gu, 2009 ). In our experiments, decrease in p53 stabilization after DNA damage was paralleled by impaired induction of p21
Waf1 , but only in cells with upregulated wild-type Twist-1 and not the S42A Twist-1 mutant. The significant reduction in G0/ G1 arrest observed in cells expressing wild-type Twist-1 or the S42E Twist-1 mutant but not in S42A Twist-1 cells provides a functional read out of the inhibitory effect of Twist-1 phosphorylation on the key cell-cycle effector p21
Waf1 . Indeed, Twist-1 was shown to override premature senescence through inhibition of p16 INK4A and p21 Waf1 promoter activation induced by H-Ras V12 and p53 in E1A-immortalized MEFs; however, the molecular mechanisms involved in this effect are still under investigation (Ansieau et al., 2008) . Further, our experiments revealed that Ser42 phosphorylation of Twist-1 desensitizes cells to DNA damage induced by adriamycin, with survival markedly decreased in S42A but not wild-type Twist-1-expressing cells (Figure 4 and Supplementary Figure S5B) . Thus, it appears that phosphorylation of the Twist-1 transcription factor by PKB in response to DNA damage contributes to an anti-apoptotic mechanism. This is in line with the strong pro-survival signaling mediated by PKB kinase. PKB itself is known to increase p53 degradation by physically associating with MDM2 and phosphorylating it at Ser166 and Ser186. This enhances its stability (Feng et al., 2004) , as well as its nuclear localization and interaction with p300, and inhibits its association with p19ARF (Zhou et al., 2001) . Interestingly, expression of the wild-type Twist-1 but not of S42A Twist-1 mutant promoted an increase in MDM2 protein levels (Figure 3b) . Therefore, it remains to be addressed whether the effect of Twist-1 Ser42 phosphorylation on p53 and the induction of its target genes are direct or mediated through other molecules. It was described previously that Twist-1 can inhibit a potent p53 transactivator homeobox protein HOXA5, compromising the p53 response to g-irradiation through suppressed induction of p21
Waf1 and inhibition of Ser20 phosphorylation (Stasinopoulos et al., 2005) . Expression of Twist-1 decreases the level of the p53 upstream activator p14 ARF , presumably by affecting production of its mRNA (Kwok et al., 2007) . Twist-1 binds to and inactivates histone acetyltransferase CBP/p300, which is required to relieve the suppressive effects of chromatin on p53 target genes (Hamamori et al., 1999) . Altogether, Twist-1 seems to act through several independent mechanisms that focus on inhibition of the p53 tumor suppressor pathway.
Our hypothesis that Twist-1 Ser42 phosphorylation might be a part of oncogenic signaling during cancer development was further supported by compelling data showing the presence of this post-translational modification in neoplastic tissue displaying high levels of activated PKB in both human and mice. The PKB pathway is often upregulated in human cancers either by overexpression or by activating mutations, which result in increased activity of the kinase.
The continuing identification of PKB substrates adds to the diverse cellular roles of the kinase, including cell growth, proliferation and survival. As phosphorylation Antisera, plasmids and reagents Flag-hTwist-1, Myc-hTwist-1 (both cloned by BamH1/Xho1 in pcDNA3) and GST-hTwist-1 (by EcoR1 in pGex4T.3) were cloned using standard PCR procedures with the full-length cDNA of the IRAUp969H1277D clone (RZPD, Berlin, Germany) as a template. Point mutations were introduced by PCR using the QuikChange site mutagenesis protocol (Stratagene, Cedar Creek, TX, USA): all primers sequences are available on request. shRNA constructs were cloned into the pTER vector. Targeting sequence used for generating shRNA against human Twist-1 was as follows: 5 0 -GCTGAGCAA GATTCAGACC-3 0 . Targeting sequences used for generating shRNA against human PKB and firefly luciferase were as described previously (Bozulic et al., 2008; Vichalkovski et al., 2008) . The reporter plasmids p21 Waf1 -Luc (el-Deiry et al., 1993) and Bax-Luc (Fogal et al., 2000) were as published, E-cadherin-Luc construct was a kind gift of A. DiFeo (The Mount Sinai School of Medicine). Antibodies recognizing total PKB, phospho-PKB (Ser473), p21
Waf1 and the phospho-(Ser/Thr) PKB substrate antibody were purchased from Cell Signaling Technology (Beverly, MA, USA); anti-p53 (DO-1) and anti-actin antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A rat monoclonal anti-tubulin (YL1/2) and mouse anti-Myc-9E10 were used as hybridoma supernatants; the antibody against Flag (M2) was from Sigma (St Louis, MO, USA). Anti-Mdm2 antibody was described previously (Feng et al., 2004) . Anti-Twist-P-Ser42 and antiTwist-P-Ser123 rabbit polyclonal antibodies were raised against synthetic peptides conjugated to keyhole limpet hemocyanin: CGGRKRRSS(PO3H2)RRSAGG peptide for the Ser42 phosphorylation site and CNVRERQRTQS (PO3H2)LNEA peptide for the Ser123 phosphorylation site. Peptide synthesis, rabbit injection and bleed collection were carried out by NeoMPS (Strasbourg, France). The antibodies were then purified on the corresponding antigenic peptides coupled to cyanogen bromide-activated Sepharose (Amersham Biosciences, Piscataway, NJ, USA). Antibodies were eluted with 0.2 M glycine, pH 2.2. Antibody specificity was confirmed by standard peptide competition. Briefly, an aliquot of the purified antibody was incubated with the phosphopeptide (at 0.5 mg/ml final concentration) in TBS buffer for 2 h on ice with agitation before western blotting. Polyclonal antibody recognizing total Twist-1 was raised in rabbits against full-length GST-fusion Twist-1 (Eurogentec, Liege, Belgium). Antisera were affinity-purified using immobilized antigen and extensively characterized.
In vitro kinase assays on peptides and GST-fusion proteins The peptides for in vitro kinase assay were synthesized by NeoMPS and further purified (Franz Fischer, FMI, Basel, Switzerland) . For a kinase reaction, we added 2 ml (100 ng) of the activated or inactivated recombinant PKBb (Yang et al., 2002) to a reaction mix containing 70 mM of the corresponding peptide (RKRRSSRRSAGG, S42/S45; RKRRSARRSAGG, S42A; RKRRSSRRAAGG, S45A; RERQRTQSLNEA, T121/S123; RERQRAQSLNEA, T121A; RERQRTQALNEA, S123A), 2 ml (2 mCi) of g-32 P-ATP and 20 mM ATP in 20 ml of kinase reaction buffer (30 mM HEPES/KOH (pH 7.4), 25 mM b-glycerophosphate, 2 mM DTT, 20 mM MgCl 2 , 0.1 mM sodium vanadate). After incubation for 30 min at 30 1C, kinase reactions were stopped with 50 mM EDTA, transferred to phosphocellulose P11 paper (Whatman, Bottmingen, Switzerland), fixed and washed four times in 1% phosphoric acid and once with acetone, dried and assayed by scintillation counting.
GST-Twist-1 or its point mutants (S42A, S123A and SS42, 123/AA) were purified from bacterial strain BL-21 according to a standard protocol. For in vitro kinase assays, we incubated 5-10 mg of GST fusion protein with 100 ng of the recombinant PKBb in the presence of 20 mM ATP in 25 ml of kinase reaction buffer for 30 min at 30 1C. The reaction was stopped by adding SDS sample buffer and protein phosphorylation was analyzed by SDS-polyacrylamide gel (PAGE) and western blotting with the phospho-(Ser/Thr) PKB substrate, anti-Twist-P-Ser42 and anti-Twist-P-Ser123 antibodies or by capillary liquid chromatography-tandem mass spectrometry (LC-MSMS, see Supplemental Materials and methods).
Mice
The PTEN þ /À mutant mice used in this study were supplied by Dr P Pandolfi (Beth Isreal Deconess Mediacl Centre, Harvard) and have been described previously (Di Cristofano et al., 1998) . Mice were housed in groups with 12-h dark/light cycles and with access to food and water ad libitum, in accordance with the Swiss Animal Protection Laws. All procedures were conducted with the appropriate approval of the Swiss authorities. For histological analysis, we dissected organs from 6-month-old wild-type and heterozygous mice, placed them in 4% paraformaldehyde/phosphate-buffered saline (PBS) and allowed to fix overnight (18 h) at 41C. Tissues were then subjected to a series of washes with PBS, 50% EtOH/PBS and 70% EtOH/PBS before being processed and embedded in paraffin using the Medite Paraffin Processing Unit (Burgdorf, Germany).
Immunohistochemistry
Paraffin-embedded slides of whole mouse embryos (E14.5) and sections of paraffin-embedded tissue microarray slides (MC2081, MCN601) (US Biomax Inc., Rockville, IN, USA) were deparaffinized, blocked by 20% normal goat serum for 1 h and then stained with aTwist-P-Ser42 antibody and phosphor-Ser473 PKB (No. 4060; Cell Signaling Technology) and counterstained with hematoxylin-eosin using standard protocol for the Discovery XT Staining Module (Ventana PKB-mediated Twist-1 phosphorylationMedical Systems, Oro Valley, AZ, USA). Images were processed with a Nikon E600 microscope system (Nikon, Melville, NY, USA).
Luciferase reporter gene assays
Harvested cells were lysed in reporter lysis buffer (25 mM Tris-phosphate, 2 mM DTT, 2 mM CDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100). Luciferase activity was determined in a luminometer (Duo Lumat LB 9507; Berthold, Bad Wildbad, Germany) by injecting 20 ml of assay buffer (40 mM Tricine, 2.14 mM (MgCO 3 ) 4 Mg(OH) 2 Â 5 H 2 O, 5.34 mM MgSO 4 , 0.2 mM EDTA, 66.6 mM DTT, 540 M CoA, 940 mM luciferin, 1.06 mM ATP) and measuring light emission for 10 s.
Cell-cycle analysis and apoptosis measurement For FACS analysis of DNA content, we trypsinized cells, fixed them in 70% ice-cold ethanol, then treated them with RNase A (10 mg) in propidium iodide solution (sodium citrate (pH 7.5), 69 mM propidium iodide) for 30 min at 37 1C and analyzed them using a FACSCalibur flow cytometer (Becton Dickinson, Bedford, MA, USA). Cells undergoing apoptosis were harvested, washed with PBS and subdivided into two fractions. One fraction was stained with JC-1 (5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide) according to the manufacturer's instructions (Molecular Probes, Eugene, OR, USA) and subjected to flow cytometry for detection of mitochondrial depolarization (DCm). Red fluorescence (FL-2 channel) of JC-1 (J-aggregates) indicated intact mitochondria, whereas green fluorescence (FL-1 channel) showed monomeric JC-1 produced by breakdown of DCm during apoptosis. The remaining cells were analyzed by western blotting.
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